BillionToOne Inc. (NASDAQ:BLLN) shares were trading lower Wednesday after Fuzzy Panda Research issued a critical report on the company and disclosed a short position.
The short seller alleged undisclosed Medicaid billing irregularities, illegal kickbacks, flaws in oncology diagnostics and unreported test failures.
• BillionToOne shares are retreating from recent levels. Why is BLLN stock falling?
BillionToOne went public in November 2025. At the time of its report, Fuzzy Panda valued the company at approximately $5.3 billion, or roughly 12 times sales, arguing that its valuation fails to account for significant regulatory and clinical risks.
Benzinga reached out to BillionToOne through email for a comment. The report will be updated upon response.
Medicaid Fraud Probes and Overbilling Allegations
Documents obtained through Freedom of Information Act requests showed that Tennessee’s Office of Program Integrity referred BillionToOne to the Tennessee Bureau of Investigation in 2024 after receiving 11 tips alleging potential fraud. According to Fuzzy Panda, state Medicaid investigators reviewed 53 claims and deemed all 53 unsupported, raising questions about the company’s billing practices. The referral does not constitute a finding of fraud.
Separate Michigan Medicaid data showed BillionToOne billed carrier screenings at an 88% attachment rate, exceeding the 40% theoretical ceiling for first-time pregnancies and rivaling Natera at 32% and Myriad Genetics Inc. (NASDAQ:MYGN) at 31%.
Fuzzy Panda estimated False Claims Act penalties could top $1.2 billion, risking over 80% of EBITDA.
Kickback Claims and Insurer Pushback
Former employees and a recording from the second quarter of 2026 cited by Fuzzy Panda allegedly showed sales representatives promising deductible caps between $99 and $349 without verifying household income, while the company billed insurers thousands of dollars for testing.
The report also flagged an undisclosed “Baby Peak” traits program and alleged that payments to doctors for blood draws and phlebotomy services could constitute illegal inducements.
Ambetter stopped accepting BillionToOne’s Unity code in 2026, according to Fuzzy Panda. The research firm also said Elevance Health Inc. (NYSE:ELV) reduced median reimbursement for the company’s carrier testing code to $9.12 before BillionToOne filed a lawsuit. Days sales outstanding increased from 38 days at the IPO to 65 days in the third quarter.
Clinical Flaws and Insider Selling
Oncologists interviewed by Fuzzy Panda questioned BillionToOne’s Northstar oncology testing business, which the short seller valued at roughly 90 times sales. Four of the five oncologists interviewed reportedly either did not recommend Northstar or had reduced their use of the tests, citing concerns about differentiation and patient monitoring.
The report also alleged that October 2026 study data comparing Northstar with Natera Inc.’s (NASDAQ:NTRA) Signatera was cherry-picked.
Separately, doctors and genetic counselors told Fuzzy Panda about alleged false-negative results involving cystic fibrosis, Down syndrome and other conditions.
Meanwhile, supplier Illumina Inc. (NASDAQ:ILMN) sued BillionToOne for patent infringement; supplier Complete Genomics joined the Department of Defense’s Chinese Military Companies list in June 2026 and insiders sold $58.5 million in stock since May 2026 while planning $24.5 million more in sales.
BLLN Price Action: BillionToOne shares were down 3.68% at $93.91 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo via Shutterstock.com
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.





